277 related articles for article (PubMed ID: 26872372)
1. Beyond evidence-based data: scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma.
Incorvaia L; Bronte G; Bazan V; Badalamenti G; Rizzo S; Pantuso G; Natoli C; Russo A
Oncotarget; 2016 Apr; 7(16):21259-71. PubMed ID: 26872372
[TBL] [Abstract][Full Text] [Related]
2. Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy.
Calvo E; Schmidinger M; Heng DY; Grünwald V; Escudier B
Cancer Treat Rev; 2016 Nov; 50():109-117. PubMed ID: 27664394
[TBL] [Abstract][Full Text] [Related]
3. Description of the EuroTARGET cohort: A European collaborative project on TArgeted therapy in renal cell cancer-GEnetic- and tumor-related biomarkers for response and toxicity.
van der Zanden LFM; Vermeulen SH; Oskarsdottir A; Maurits JSF; Diekstra MHM; Ambert V; Cambon-Thomsen A; Castellano D; Fritsch A; Garcia Donas J; Guarch Troyas R; Guchelaar HJ; Hartmann A; Hulsbergen-van de Kaa C; Jaehde U; Junker K; Martinez-Cardus A; Masson G; Oosterwijk-Wakka J; Radu MT; Rafnar T; Rodriguez-Antona C; Roessler M; Ruijtenbeek R; Stefansson K; Warren A; Wessels L; Eisen T; Kiemeney LALM; Oosterwijk E
Urol Oncol; 2017 Aug; 35(8):529.e9-529.e16. PubMed ID: 28385611
[TBL] [Abstract][Full Text] [Related]
4. Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma.
Li S; Kong Y; Si L; Chi Z; Cui C; Sheng X; Guo J
BMC Cancer; 2014 May; 14():376. PubMed ID: 24886512
[TBL] [Abstract][Full Text] [Related]
5. Pattern of Care Study in Metastatic Renal-Cell Carcinoma in the Preimmunotherapy Era in Switzerland.
Sandmeier N; Rothschild SI; Rothermundt C; Cathomas R; Schardt J; Berthold D; von Burg P; Müller B; Beyer J; Vogt DR; Stenner F
Clin Genitourin Cancer; 2018 Aug; 16(4):e711-e718. PubMed ID: 29503245
[TBL] [Abstract][Full Text] [Related]
6. The Wide Experience of the Sequential Therapy for Patients with Metastatic Renal Cell Carcinoma.
Lambea J; Anido U; Etxániz O; Flores L; Montesa Á; Sepúlveda JM; Esteban E
Curr Oncol Rep; 2016 Nov; 18(11):66. PubMed ID: 27613167
[TBL] [Abstract][Full Text] [Related]
7. Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: optimizing patient benefit.
Oudard S; Elaidi RT
Cancer Treat Rev; 2012 Dec; 38(8):981-7. PubMed ID: 22289686
[TBL] [Abstract][Full Text] [Related]
8. Current and Emerging Treatments for Metastatic Renal Cell Carcinoma.
Cavaliere C; D'Aniello C; Pepa CD; Pisconti S; Berretta M; Facchini G
Curr Cancer Drug Targets; 2018; 18(5):468-479. PubMed ID: 28183256
[TBL] [Abstract][Full Text] [Related]
9. Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma.
de Velasco G; Bex A; Albiges L; Powles T; Rini BI; Motzer RJ; Heng DYC; Escudier B
Eur Urol Oncol; 2019 Sep; 2(5):505-514. PubMed ID: 31377308
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxic chemotherapy in the treatment of advanced renal cell carcinoma in the era of targeted therapy.
Diamond E; Molina AM; Carbonaro M; Akhtar NH; Giannakakou P; Tagawa ST; Nanus DM
Crit Rev Oncol Hematol; 2015 Dec; 96(3):518-26. PubMed ID: 26321263
[TBL] [Abstract][Full Text] [Related]
11. Recent advances in the treatment of advanced renal cell carcinoma: towards multidisciplinary personalized care.
Bex A; Gore M; Mulders P; Sternberg CN
BJU Int; 2012 Nov; 110(9):1289-300. PubMed ID: 22624610
[TBL] [Abstract][Full Text] [Related]
12. Sequential treatment strategies and combination therapy regimens in metastatic renal cell carcinoma.
Pal SK; Vogelzang NJ
Clin Adv Hematol Oncol; 2013 Mar; 11(3):146-55. PubMed ID: 23598982
[TBL] [Abstract][Full Text] [Related]
13. Targeted Therapy for Metastatic Renal Cell Carcinoma.
Afriansyah A; Hamid AR; Mochtar CA; Umbas R
Acta Med Indones; 2016 Oct; 48(4):335-347. PubMed ID: 28143997
[TBL] [Abstract][Full Text] [Related]
14. Controversies in renal cell carcinoma: treatment choice after progression on vascular endothelial growth factor-targeted therapy.
Calvo E; Grünwald V; Bellmunt J
Eur J Cancer; 2014 May; 50(7):1321-9. PubMed ID: 24594299
[TBL] [Abstract][Full Text] [Related]
15. Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors.
Turnbull JD; Cobert J; Jaffe T; Harrison MR; George DJ; Armstrong AJ
Clin Genitourin Cancer; 2013 Mar; 11(1):45-50. PubMed ID: 23041453
[TBL] [Abstract][Full Text] [Related]
16. Current evidence and the evolving role of sunitinib in the management of renal cell carcinoma.
Noronha V; Joshi A; Bakshi G; Tongaonkar H; Prabhash K
Indian J Cancer; 2016; 53(1):102-8. PubMed ID: 27146754
[TBL] [Abstract][Full Text] [Related]
17. Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIM
Fishman M; Dutcher JP; Clark JI; Alva A; Miletello GP; Curti B; Agarwal N; Hauke R; Mahoney KM; Moon H; Treisman J; Tykodi SS; Daniels G; Morse MA; Wong MKK; Kaufman H; Gregory N; McDermott DF
J Immunother Cancer; 2019 Mar; 7(1):84. PubMed ID: 30917871
[TBL] [Abstract][Full Text] [Related]
18. Advanced renal cell carcinoma: current and emerging management strategies.
Escudier B
Drugs; 2007; 67(9):1257-64. PubMed ID: 17547470
[TBL] [Abstract][Full Text] [Related]
19. New perspectives in the treatment of metastatic renal cell carcinoma.
Barrière J; Hoch B; Ferrero JM
Crit Rev Oncol Hematol; 2012 Dec; 84 Suppl 1():e16-23. PubMed ID: 22099727
[TBL] [Abstract][Full Text] [Related]
20. Successes and limitations of targeted therapies in renal cell carcinoma.
Pracht M; Berthold D
Prog Tumor Res; 2014; 41():98-112. PubMed ID: 24727990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]